The RapidSense methamphetamine test is said to be the first of QuantRx’s drugs-of-abuse (DOA) tests based solely on its proprietary technology approved by the FDA. The RapidSense methamphetamine
The first Phase II trial will study the effects of multiple doses of CMX001 given to stem cell and kidney transplant recipients with BK viruria. Further studies are
Pursuant to the terms of the agreement, Impulse Monitoring (IMI) will offer to all of Health Management Associates’s (HMA) 56 hospitals its comprehensive intraoperative neuromonitoring (IONM) services, including
In addition to the closing purchase price, Isis will receive earn out payments from Abbott tied to post-closing sales of Ibis systems, including instruments and assay kits. Previously,
Located in regions of the brain responsible for Parkinson’s disease, Omeros is the first to link its novel target to the treatment of any movement disorder, including Parkinson’s
Under the agreement, Keata will be the third party supplier to the multi-national consumer healthcare company for the products for an initial two-year term commencing from January 1,
Previously, Duramed, a subsidiary of Barr Pharmaceuticals, has announced that the FDA has accepted for review its biologics license application for the vaccines. The vaccines will be used
The license authorized making and selling cellular and animal models in a restricted field, for research uses only expressly excluding the use of such product for any commercial
The new prescription acne treatment received approval from the FDA in December, 2008 and will be on pharmacy shelves in the US in the first quarter of 2009.
Neosalus, formulated with Quinnova’s patented Proderm Technology, provides skin barrier repair, protection, and moisturization. Christopher Hensby, senior vice president of Quinnova, said: “To treat recalcitrant skin conditions such
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.